Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team Open Registration April 27 12:00-1:00PM ET

[lankisterguy]

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team Live Simulcast |

Register now for this interactive CME/CE/CPE-certified workshop to gain expert insight on current best practices and emerging strategies for advances in chronic lymphocytic leukemia care.

Register Now clinicaloptions.com/events/...

Who Should Attend: This program is intended for community-based medical hematologists/oncologists, nurses, pharmacists, advanced practice providers, and other healthcare professionals involved in the treatment of patients with CLL.

Thursday, April 27, 2023 Virtual 12:00 PM - 1:00 PM Eastern Time (ET)

Royal Oak, Michigan - Faculty - Nirav Shah, MD Associate Professor of Medicine

Division of Hematology and Oncology Medical College of Wisconsin Milwaukee, Wisconsin

-

Agenda

• Introduction

• Case Discussions: Individualizing Care of Patients with CLL/SLL

- Key Variables in Making Treatment Decisions

- Classes of Agents: Mechanism of Action, Selectivity, Specificity and Associated Adverse Events

- Recent Data on Advances in the Treatment of CLL/SLL

- Optimal and effective management of CLL/SLL

• Partnering With Patients in Their Care

- Discussing Patient Treatment Goals and Expectations

- Best Practices in Patient Care

- Effective Communication of New or Worsening Symptoms with Healthcare Professionals

• Final Thoughts and Audience Question and Answer Session

-

This program will provide expert perspectives to facilitate state-of-the-art clinical management strategies for patients with CLL/SLL, including information on the latest practice impacting data on recent advances in the personalization of care for patients with CLL/SLL.

Goal Statement

The goal of this program is to improve the knowledge, confidence, and competence of multidisciplinary team learners in the care of patients with CLL using evidence-based and guideline-directed best practices.

-

Learning Objectives

Upon completion of this activity, participants should be able to:

Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration available clinical data, the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference

Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL

Develop multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial-related and age-related disparities in care

Manage treatment-related symptoms in patients with CLL/SLL using guidelines and expert recommendations based on real-world experience to optimally adjust, discontinue, or change the patient’s current therapeutic plan

Evaluate the evolving role of measurable/minimal residual disease, allogeneic hematopoietic cell transplant, CAR T-cell therapy, and other novel therapeutics for CLL/SLL

12:00 PM - 1:00 PM ET

11:00 AM – 12:00 PM CT

9:00 AM – 10:00 AM PT

18.00 - 19.00 CEST

Share With Your Colleagues:

We invite you to share this complimentary event with your colleagues by forwarding this email.

Questions? Contact us! link.mycea.com/NDIzLU1OUC03... Provided by Clinical Care Options LLC